Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias

European Archives of Psychiatry and Clinical Neuroscience

Volumn 262, Issue 2 SUPPL., 2012, Pages

  Genius, J ^a   Klafki, H ^a   Benninghoff, J ^a   Esselmann, H ^a   Wiltfang, J ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Alzheimer's dementia; Biomarkers; Differential diagnosis; Genotyping; Mild cognitive impairment

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; BRAIN BIOPSY; DEMENTIA; DIFFERENTIAL DIAGNOSIS; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MILD COGNITIVE IMPAIRMENT; NEUROCHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REVIEW; SENSITIVITY AND SPECIFICITY; CEREBROSPINAL FLUID; DEGENERATIVE DISEASE; GENETIC PREDISPOSITION; GENETICS; NEUROIMAGING; PREDICTIVE VALUE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEURODEGENERATIVE DISEASES; NEUROIMAGING; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; TAU PROTEINS;

EID: 84876016477     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-012-0362-3     Document Type: Review

References (70)

1. Albert MS, DeKosky ST et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3):270-279
2. Alexander GE, Chen K et al (2002) Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatr 159(5):738-745
3. Anchisi D, Borroni B et al (2005) Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 62(11):1728-1733
4. Andreasson U, Portelius E et al (2007) Aspects of beta-amyloid as a biomarker for Alzheimer's disease. Biomarkers Med 1(1):59-78
5. Arai H, Ishiguro K et al (2000) CSF phosphorylated tau protein and mild cognitive impairment: a prospective study. Exp Neurol 166(1):201-203
6. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2(10):605-613
7. Blennow K, Vanmechelen E et al (2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Mol Neurobiol 24(1-3):87-97
8. Buee L, Bussiere T et al (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33(1):95-130
9. Buerger K, Ewers M et al (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain J Neurol 129(Pt 11):3035-3041
10. Buerger K, Teipel SJ et al (2002) CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59(4):627-629
11. Chetelat G, Desgranges B et al (2003) Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 60(8):1374-1377
12. Clarfield AM (2003) The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med 163(18):2219-2229
13. Fagan AM, Mintun MA et al (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59(3):512-519
14. Fagan AM, Mintun MA et al (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 1(8-9):371-380
15. Farrer LA, Cupples LA et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278(16):1349-1356
16. Ferri CP, Prince M et al (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366(9503):2112-2117
17. Frankfort SV, Tulner LR et al (2008) Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. Curr Clin Pharmacol 3(2):123-131
18. Hampel H, Broich K et al (2009) Biological markers for early detection and pharmacological treatment of Alzheimer's disease. Dialogues Clin Neurosci 11(2):141-157
19. Hampel H, Buerger K et al (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatr 61(1):95-102
20. Hampel H, Burger K et al (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 4(1):38-48
21. Hampel H, Frank R et al (2010) Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 9(7):560-574
22. Hampel H, Wilcock G et al (2011) Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 95(4):579-593
23. Hansson O, Zetterberg H et al (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3):228-234
24. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580):353-356
25. Harold D, Abraham R et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41(10):1088-1093
26. Haroutunian V, Schnaider-Beeri M et al (2008) Role of the neuropathology of Alzheimer disease in dementia in the oldest-old. Arch Neurol 65(9):1211-1217
27. Hollingworth P, Harold D et al (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 43(5):429-435
28. Hu YY, He SS et al (2002) Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 320(3):156-160
29. Jack CR Jr, Albert MS et al (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3):257-262
30. Jonsson T, Atwal JK et al (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488(7409):96-99
31. Kim J, Basak JM et al (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63(3):287-303
32. Klunk WE, Engler H et al (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55(3):306-319
33. Kornhuber J, Schmidtke K et al (2009) Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. Dement Geriatr Cogn Disord 27(5):404-417
34. Lambert JC, Heath S et al (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41(10):1094-1099
35. Li G, Sokal I et al (2007) CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69(7):631-639
36. Mandelkow EM, Mandelkow E (1998) Tau in Alzheimer's disease. Trends Cell Biol 8(11):425-427
37. Manolio TA, Collins FS et al (2009) Finding the missing heritability of complex diseases. Nature 461(7265):747-753
38. Mattsson N, Andreasson U et al (2011) The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7(4):386-395
39. Mattsson N, Zetterberg H et al (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302(4):385-393
40. Mayeux R, Saunders AM et al (1998) Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 338(8):506-511
41. McKhann G, Drachman D et al (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7):939-944
42. McKhann GM, Knopman DS et al (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3):263-269
43. Middleton LE, Grinberg LT et al (2011) Neuropathologic features associated with Alzheimer disease diagnosis: age matters. Neurology 77(19):1737-1744
44. Mitchell AJ (2009) CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies. J Neurol Neurosurg Psychiatry 80(9):966-975
45. Okello A, Koivunen J et al (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73(10):754-760
46. Otto M, Wiltfang J et al (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58(2):192-197
47. Reivich M, Kuhl D et al (1979) The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 44(1):127-137
48. Richard E, Schmand B et al (2012) The Alzheimer myth and biomarker research in Dementia. J Alzheimers Dis, JAD
49. Risacher SL, Saykin AJ et al (2009) Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 6(4):347-361
50. Roses AD (1995) Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann Neurol 38(1):6-14
51. Rowe CC, Ackerman U et al (2008) Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7(2):129-135
52. Saunders AM, Hulette O et al (1996) Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet 348(9020):90-93
53. Savva GM, Wharton SB et al (2009) Age, neuropathology, and dementia. N Engl J Med 360(22):2302-2309
54. Schmidt C, Wolff M et al (2011) Rapidly progressive Alzheimer disease. Arch Neurol 68(9):1124-1130
55. Schoonenboom NS, Reesink FE et al (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78(1):47-54
56. Seppala TT, Nerg O et al (2012) CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 78(20):1568-1575
57. Shaw LM, Vanderstichele H et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65(4):403-413
58. Shoji M, Matsubara E et al (1998) Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease. J Neurol Sci 158(2):134-140
59. Snider BJ, Fagan AM et al (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 66(5):638-645
60. Sperling RA, Aisen PS et al (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3):280-292
61. Strozyk D, Blennow K et al (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60(4):652-656
62. Sunderland T, Linker G et al (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289(16):2094-2103
63. Teipel SJ, Meindl T et al (2008) Novel MRI techniques in the assessment of dementia. Euro J Nucl Med Mol Imaging 35(Suppl 1):S58-S69
64. Thal DR, Rub U et al (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58(12):1791-1800
65. Vemuri P, Wiste HJ et al (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73(4):287-293
66. Visser PJ, Verhey F et al (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 8(7):619-627
67. Welge V, Fiege O et al (2009) Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. J Neural Trans 116(2):203-212
68. Wiltfang J, Otto M et al (1999) Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurochem 73(6):2485-2490
69. Zerr I, Bodemer M et al (1998) Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol 43(1):32-40
70. Zetzsche T, Rujescu D et al (2010) Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. Expert Rev Mol Diagn 10(5):667-690